Most Read Articles
Elaine Soliven, 27 Sep 2017
A second dose of kisspeptin-54 improves oocyte yield in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) treatment, according to a recent study.
23 Oct 2017
Pearl Toh spoke with Dr Teh Ming Ming, senior consultant at the Department of Endocrinology, Singapore General Hospital (SGH), on the major challenges of diagnosing and managing diabetes in primary care, in conjunction with the World Diabetes Day on 14 November. Awareness of the symptoms of diabetes is important, and patients should be empowered to manage their conditions.
Rachel Soon, 2 days ago

Pharmacists can and should utilize their positions within communities to provide access to an extended range of healthcare services, says an expert.

01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Tamoxifen use in breast cancer not linked to acute pancreatitis

17 Mar 2017
There are studies ongoing to grow human organs in pigs to help address lack of organs for transplants.

The use of tamoxifen in breast cancer patients is not associated with the incidence of acute pancreatitis (AP), a new study shows.

The population-based cohort study used data from the National Health Insurance Research Database of Taiwan. New-onset breast cancer patients at least 20 years of age were included. Those with histories of pancreatic cancer and acute and chronic pancreatitis were excluded.

The accumulated defined daily dose (DDD) of tamoxifen prescribed during the follow-up periodwas calculated. Prescription information was calculated yearly after the index date to account for changes in drug use over time.

Before propensity score matching, 22,005 patients (mean age53.4 years)did not receive tamoxifen while 40,484 did (mean age 51.4 years). Asthma (p=0.01) and hyperlipidaemia (p<0.001) were more common in nonusers while fluorouracil use was more common in tamoxifen users (p<0.001). Differences disappeared after propensity score matching.

Alcohol-related diseases (adjusted hazard ratio [aHR], 1.56; 95 percent CI, 0.50 to 4.88), despite being known to cause chronic and acute pancreatitis, were not associated with AP after controlling for age. Similarly, hepatitis B (aHR, 1.15; 0.62 to 2.10) and hepatitis C (aHR, 1.28; 0.63 to 2.61) virus infections were also not associated with AP.

On the other hand, diabetes mellitus (aHR, 1.63; 1.23 to 2.61) and gallstones (aHR, 3.19; 2.33 to 4.35) correlated with an increased risk of AP after controlling for age.

After adjustment for age, comorbidities and medications, the risk of AP was not significant between tamoxifen users and nonusers (aHR, 0.94; 0.74 to 1.19) in the nonmatching cohorts. No dose–response trend existed between tamoxifen use and the risk of AP (aHR, 0.98; 0.96 to 1.00).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elaine Soliven, 27 Sep 2017
A second dose of kisspeptin-54 improves oocyte yield in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) treatment, according to a recent study.
23 Oct 2017
Pearl Toh spoke with Dr Teh Ming Ming, senior consultant at the Department of Endocrinology, Singapore General Hospital (SGH), on the major challenges of diagnosing and managing diabetes in primary care, in conjunction with the World Diabetes Day on 14 November. Awareness of the symptoms of diabetes is important, and patients should be empowered to manage their conditions.
Rachel Soon, 2 days ago

Pharmacists can and should utilize their positions within communities to provide access to an extended range of healthcare services, says an expert.

01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.